Product category:
Cell/tissue handling and counting
News Release from: Acumen Biosciences | Subject: Explorer
Edited by the Laboratorytalk Editorial
Team on 10 June 2003
Neurite outgrowth assays for primary
screening
High throughput, live cell, neurite outgrowth screens can be performed in 384 well plates at rates exceeding 30,000 compounds per day without compromising data quality
With their ability to combine high content and high throughput, Explorer detection systems from Acumen Bioscience have, says the company, eliminated the need for neuritogenesis screeners to choose between speed and resolution For the first time, high throughput, live cell, neurite outgrowth screens can be performed in 384 well plates at rates exceeding 30,000 compounds per day, and without compromising data quality
This article was originally published on Laboratorytalk on 25 Feb 2003 at 8.00am (UK)
Related stories
Defining cell based screening
Enhanced software to meet the increasing demands of high throughput cellular screening is compatible with 24 to 1536-well systems
Haematology analyser fills gap in range
With a throughput of 80 samples per hour, this will suit laboratories with workloads of up to 350 samples per day and fills the gap between 60 and 120 sample per hour machines
Innovative new products emphasise R and D
Completely new bench-top analyser combines the latest technological advances and a large test menu with a faster throughput
This capability opens up new avenues of investigation for the neurobiologist.
Physical limitations of existing sytems have, to date, restricted scientists to screens of small focussed libraries of compounds on fixed cells.
Potentially efficacious compounds may have been excluded because of the logistical difficulties running larger screens.
Furthermore the use of fixed cells of non-human origin are sub-optimal for the discovery of drugs that will be active on live human cells.
The enhanced sensitivity afforded by the Explorer laser scanning fluorescence detection systems, compared with camera-based alternatives, means that analysis can be carried out as early as two days after neurite stimulation.
An additional benefit is that working with a live cell system allows the experiment to be continued for collection of data from later timepoints.
In this way any slower acting compounds will not be overlooked.
With these advantages, Acumen thinks its Explorer is set to become the system of choice for drug discovering in field of CNS diseases.
• Acumen Biosciences: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
